{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:05:23Z","timestamp":1791475523123,"version":"4.3.4"},"reference-count":66,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010618","name":"Guangzhou University of Traditional Chinese Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010618","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013093","name":"Science and Technology Planning Project of Shenzhen Municipality","doi-asserted-by":"publisher","award":["JSGG20191129102216637"],"award-info":[{"award-number":["JSGG20191129102216637"]}],"id":[{"id":"10.13039\/501100013093","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013093","name":"Science and Technology Planning Project of Shenzhen Municipality","doi-asserted-by":"publisher","award":["KCXFZ20201221173612034"],"award-info":[{"award-number":["KCXFZ20201221173612034"]}],"id":[{"id":"10.13039\/501100013093","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.heliyon.2023.e15310","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T02:46:04Z","timestamp":1681181164000},"page":"e15310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"9","author":[{"given":"Qiyan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingna","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huisheng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunling","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Airong","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunmin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.heliyon.2023.e15310_bib1","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3949\/ccjm.83a.15065","article-title":"Anemia of chronic kidney disease: treat it, but not too aggressively","volume":"83","author":"Nakhoul","year":"2016","journal-title":"Cleve. Clin. J. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e15310_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ajkd.2014.10.013","article-title":"Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management","volume":"65","author":"Akbari","year":"2015","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e15310_bib3","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.ajkd.2017.09.026","article-title":"Update on anemia in ESRD and earlier stages of CKD: core curriculum 2018","volume":"71","author":"Fishbane","year":"2018","journal-title":"Am. J. Kidney Dis."},{"issue":"21","key":"10.1016\/j.heliyon.2023.e15310_bib4","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e15310_bib5","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","article-title":"Roxadustat for the maintenance treatment of anemia in patients with end-stage kidney disease on stable dialysis: a European phase 3, randomized, open-label, active-controlled study (pyrenees)","volume":"38","author":"Csiky","year":"2021","journal-title":"Adv. Ther."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e15310_bib6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1053\/j.ajkd.2016.05.031","article-title":"Spectrum and burden of erythropoiesis-stimulating agent hyporesponsiveness among contemporary hemodialysis patients","volume":"68","author":"Luo","year":"2016","journal-title":"Am. J. Kidney Dis."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e15310_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1440-1797.2007.00810.x","article-title":"Erythropoiesis-stimulating agent hyporesponsiveness","volume":"12","author":"Johnson","year":"2007","journal-title":"Nephrology"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e15310_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155805","article-title":"Comparative effectiveness of biosimilar, reference product and other erythropoiesis-stimulating agents (ESAs) still covered by patent in chronic kidney disease and cancer patients: an Italian population-based study","volume":"11","author":"Ingrasciotta","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2023.e15310_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1471-2369-14-44","article-title":"Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics","volume":"14","author":"Gilbertson","year":"2013","journal-title":"BMC Nephrol."},{"issue":"20","key":"10.1016\/j.heliyon.2023.e15310_bib10","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e15310_bib11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.kint.2015.10.002","article-title":"Iron management in chronic kidney disease: conclusions from a \"kidney disease: improving global outcomes\" (KDIGO) controversies conference","volume":"89","author":"Macdougall","year":"2016","journal-title":"Kidney Int."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e15310_bib12","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2174\/157489006777442522","article-title":"Novel drugs and the response to hypoxia: HIF stabilizers and prolyl hydroxylase","volume":"1","author":"Nangaku","year":"2006","journal-title":"Recent Pat. Cardiovasc. Drug Discov."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e15310_bib13","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e15310_bib14","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.cmet.2008.12.012","article-title":"Intestinal hypoxia-inducible transcription factors are essential for iron absorption following iron deficiency","volume":"9","author":"Shah","year":"2009","journal-title":"Cell Metabol."},{"key":"10.1016\/j.heliyon.2023.e15310_bib15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.freeradbiomed.2018.07.018","article-title":"An intimate crosstalk between iron homeostasis and oxygen metabolism regulated by the hypoxia-inducible factors (HIFs)","volume":"133","author":"Hirota","year":"2019","journal-title":"Free Radic. Biol. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2023.e15310_bib16","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1172\/JCI38499","article-title":"HIF-2alpha, but not HIF-1 alpha, promotes iron absorption in mice","volume":"119","author":"Mastrogiannaki","year":"2009","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.heliyon.2023.e15310_bib17","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing long-term dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e15310_bib18","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.ajkd.2015.12.020","article-title":"Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: a phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study","volume":"67","author":"Provenzano","year":"2016","journal-title":"Am. J. Kidney Dis."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e15310_bib19","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1093\/ndt\/gfab051","article-title":"Roxadustat for anemia in patients with end-stage renal disease incident to dialysis","volume":"36","author":"Provenzano","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e15310_bib20","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1681\/ASN.2014111139","article-title":"Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia","volume":"27","author":"Holdstock","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e15310_bib21","first-page":"592","article-title":"Efficacy and safety of daprodustat for treatment of anemia of chronic kidney disease in incident dialysis patients: a randomized clinical trial","volume":"182","author":"Singh","year":"2022","journal-title":"JAMA Intern"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e15310_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med."},{"key":"10.1016\/j.heliyon.2023.e15310_bib23","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7650","key":"10.1016\/j.heliyon.2023.e15310_bib24","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.heliyon.2023.e15310_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155050","article-title":"The effect of vitamin d-calcium co-supplementation on inflammatory biomarkers: a systematic review and meta-analysis of randomized controlled trials","volume":"129","author":"Asbaghi","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.heliyon.2023.e15310_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med. Res. Methodol."},{"key":"10.1016\/j.heliyon.2023.e15310_bib27","author":"Higgins","year":"2008"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e15310_bib28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/jrsm.38","article-title":"Review: Cochrane handbook for systematic reviews for interventions, Version 5.1.0, published 3\/2011","volume":"2","author":"Shuster","year":"2011","journal-title":"Res. Synth. Methods"},{"issue":"8","key":"10.1016\/j.heliyon.2023.e15310_bib29","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/ndt\/gfx011","article-title":"Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China","volume":"32","author":"Chen","year":"2017","journal-title":"Nephrol. Dial. Transplant."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e15310_bib30","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2215\/CJN.02510218","article-title":"Effects of molidustat in the treatment of anemia in CKD","volume":"14","author":"Macdougall","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e15310_bib31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ckj\/sfy014","article-title":"Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis","volume":"12","author":"Meadowcroft","year":"2019","journal-title":"Clin Kidney J"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e15310_bib32","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1681\/ASN.2019060623","article-title":"Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on hemodialysis in Japan","volume":"31","author":"Akizawa","year":"2020","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e15310_bib33","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.16011219","article-title":"Efficacy and safety of daprodustat compared with darbepoetin alfa in Japanese hemodialysis patients with anemia: a randomized, double-blind, phase 3 trial","volume":"15","author":"Akizawa","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e15310_bib34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jfma.2021.06.004","article-title":"Roxadustat treatment for anemia in peritoneal dialysis patients: a randomized controlled trial","volume":"121","author":"Hou","year":"2022","journal-title":"J. Formos. Med. Assoc."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e15310_bib35","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1159\/000517053","article-title":"A phase 3 study of enarodustat (JTZ-951) in Japanese hemodialysis patients for treatment of anemia in chronic kidney disease: SYMPHONY HD study","volume":"7","author":"Akizawa","year":"2021","journal-title":"Kidney Dis."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e15310_bib36","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1093\/ndt\/gfab055","article-title":"Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study","volume":"36","author":"Nangaku","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e15310_bib37","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.ekir.2021.04.007","article-title":"A randomized trial of roxadustat in anemia of kidney failure: SIERRAS study","volume":"6","author":"Charytan","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"25","key":"10.1016\/j.heliyon.2023.e15310_bib38","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1056\/NEJMoa2113379","article-title":"Daprodustat for the treatment of anemia in patients undergoing dialysis","volume":"385","author":"Singh","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.heliyon.2023.e15310_bib39","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e15310_bib40","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.ekir.2021.07.015","article-title":"Molidustat for Japanese patients with renal anemia receiving dialysis","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e15310_bib41","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000523949","article-title":"Desidustat in anemia due to dialysis-dependent chronic kidney disease: a phase 3 study (DREAM-D)","volume":"53","author":"Gang","year":"2022","journal-title":"Am. J. Nephrol."},{"issue":"4","key":"10.1016\/j.heliyon.2023.e15310_bib42","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1681\/ASN.2020111638","article-title":"Roxadustat versus epoetin alfa for treating anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study","volume":"33","author":"Fishbane","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.heliyon.2023.e15310_bib43","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000516901","article-title":"Managing anemia across the stages of kidney disease in those hyporesponsive to erythropoiesis-stimulating agents","volume":"52","author":"Weir","year":"2021","journal-title":"Am. J. Nephrol."},{"issue":"10","key":"10.1016\/j.heliyon.2023.e15310_bib44","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41581-019-0182-z","article-title":"Mechanisms of hypoxia signalling: new implications for nephrology","volume":"15","author":"Schodel","year":"2019","journal-title":"Nat. Rev. Nephrol."},{"issue":"32","key":"10.1016\/j.heliyon.2023.e15310_bib45","doi-asserted-by":"crossref","first-page":"20055","DOI":"10.1074\/jbc.272.32.20055","article-title":"Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1","volume":"272","author":"Rolfs","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"34","key":"10.1016\/j.heliyon.2023.e15310_bib46","doi-asserted-by":"crossref","first-page":"24142","DOI":"10.1074\/jbc.274.34.24142","article-title":"Transferrin receptor induction by hypoxia. HIF-1-mediated transcriptional activation and cell-specific post-transcriptional regulation","volume":"274","author":"Tacchini","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"34","key":"10.1016\/j.heliyon.2023.e15310_bib47","doi-asserted-by":"crossref","first-page":"24147","DOI":"10.1074\/jbc.274.34.24147","article-title":"Identification of a hypoxia response element in the transferrin receptor gene","volume":"274","author":"Lok","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"28","key":"10.1016\/j.heliyon.2023.e15310_bib48","doi-asserted-by":"crossref","first-page":"21048","DOI":"10.1074\/jbc.M000636200","article-title":"Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency","volume":"275","author":"Mukhopadhyay","year":"2000","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e15310_bib49","doi-asserted-by":"crossref","first-page":"5375","DOI":"10.1074\/jbc.272.9.5375","article-title":"Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia","volume":"272","author":"Lee","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.heliyon.2023.e15310_bib50","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1182\/blood-2011-09-380337","article-title":"Deletion of HIF-2alpha in the enterocytes decreases the severity of tissue iron loading in hepcidin knockout mice","volume":"119","author":"Mastrogiannaki","year":"2012","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.heliyon.2023.e15310_bib51","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1038\/nrneph.2015.82","article-title":"Anaemia in kidney disease: harnessing hypoxia responses for therapy","volume":"11","author":"Koury","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"issue":"7","key":"10.1016\/j.heliyon.2023.e15310_bib52","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1053\/j.gastro.2011.03.007","article-title":"Hypoxia-inducible factor-2alpha mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice","volume":"140","author":"Taylor","year":"2011","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e15310_bib53","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1681\/ASN.2006070802","article-title":"Molecular control of iron transport","volume":"18","author":"Ganz","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"12","key":"10.1016\/j.heliyon.2023.e15310_bib54","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1172\/JCI63924","article-title":"Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis","volume":"122","author":"Liu","year":"2012","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e15310_bib55","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1172\/JCI122359","article-title":"Hepatic hepcidin\/intestinal HIF-2alpha axis maintains iron absorption during iron deficiency and overload","volume":"129","author":"Schwartz","year":"2019","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.heliyon.2023.e15310_bib56","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","article-title":"Anemia of inflammation","volume":"133","author":"Weiss","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.heliyon.2023.e15310_bib57","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exphem.2015.11.007","article-title":"Hematopoietic niches, erythropoiesis and anemia of chronic infection","volume":"44","author":"Gomes","year":"2016","journal-title":"Exp. Hematol."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e15310_bib58","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/ndt\/gfn543","article-title":"Impact of elevated C-reactive protein levels on erythropoiesis- stimulating agent (ESA) dose and responsiveness in hemodialysis patients","volume":"24","author":"Bradbury","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"10.1016\/j.heliyon.2023.e15310_bib59","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1182\/blood-2003-03-0672","article-title":"Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation","volume":"102","author":"Ganz","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2023.e15310_bib60","article-title":"253 evaluation of FG4592, a novel oral hypoxia-inducible factor prolyl hydroxylase inhibitor, to treat anemia in hemodialysis patients","volume":"57","author":"Provenzano","year":"2011","journal-title":"American Journal of Kidney Diseases - AMER J KIDNEY DIS."},{"issue":"9","key":"10.1016\/j.heliyon.2023.e15310_bib61","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.bbamcr.2012.01.014","article-title":"Hepcidin and iron homeostasis","volume":"1823","author":"Ganz","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"5","key":"10.1016\/j.heliyon.2023.e15310_bib62","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1073\/pnas.0409409102","article-title":"Iron release from macrophages after erythrophagocytosis is up-regulated by ferroportin 1 overexpression and down-regulated by hepcidin","volume":"102","author":"Knutson","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.heliyon.2023.e15310_bib63","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.642296","article-title":"Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents","volume":"8","author":"Portoles","year":"2021","journal-title":"Front. Med."},{"issue":"17","key":"10.1016\/j.heliyon.2023.e15310_bib64","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2009-09-245977","article-title":"Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia","volume":"115","author":"Sasu","year":"2010","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.heliyon.2023.e15310_bib65","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1039\/C7SC02103H","article-title":"Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials","volume":"8","author":"Yeh","year":"2017","journal-title":"Chem. Sci."},{"issue":"8","key":"10.1016\/j.heliyon.2023.e15310_bib66","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.16191020","article-title":"Efficacy and cardiovascular safety of roxadustat for treatment of anemia in patients with non-dialysis-dependent CKD: pooled results of three randomized clinical trials","volume":"16","author":"Provenzano","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023025173?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844023025173?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:00:06Z","timestamp":1778598006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844023025173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2405844023025173"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e15310","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors versus erythropoiesis-stimulating agents on iron metabolism and inflammation in patients undergoing dialysis: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2023.e15310","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e15310"}}